Quantcast

Latest Valeant Pharmaceuticals Stories

2014-04-24 16:29:08

LAVAL, Quebec, April 24, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) and Pershing Square Capital Management L.P. ("Pershing Square") today announced that they have released the webcast replay and accompanying presentations from the April 22, 2014 investor meeting featuring Valeant Chairman and Chief Executive Officer, J. Michael Pearson and Pershing Square Chief Executive Officer, William A. Ackman, outlining Valeant's proposed acquisition of...

2014-04-24 12:30:07

LAVAL, Quebec, April 24, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Thursday, May 8, 2014 at 8:00 a.m. ET (5:00 a.m. PT) to discuss results for the 2014 first quarter. The dial-in number to participate on this call is (877) 876-8393, confirmation code 28376511. International callers should dial (973) 200-3961, confirmation...

2014-04-23 08:31:50

LAVAL, Quebec, April 23, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today its nominees to stand for election to the Board of Directors at its annual meeting of shareholders on May 20, 2014. Given Valeant's increased size as a company and its ability to look at a broader set of business development opportunities, three of our Directors, who have full-time jobs looking at healthcare investment opportunities, feel that continued...

2014-04-22 08:32:39

This Offer Represents a Substantial Premium to Allergan's Unaffected Stock Price of $116.63 on April 10, 2014, the Day Before Pershing Square Crossed the 5% Schedule 13D Ownership Level and Commenced its Rapid Accumulation Program LAVAL, Quebec, April 22, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) announced today that it has submitted a merger proposal to the Board of Directors of Allergan, Inc. (NYSE: AGN) under which each Allergan...

2014-04-11 08:22:40

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, April 11, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Eli Lilly & Co. (NYSE: LLY), UnitedHealth Group, Inc. (NYSE: UNH), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Forest Laboratories Inc. (NYSE: FRX), and Zoetis Inc. (NYSE: ZTS). Private wealth members receive these notes ahead of publication. To reserve complementary membership,...

2014-04-10 08:28:43

DUBLIN, Apr. 10, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/pnf52x/global ) has announced the addition of the "Global Dermatophytic Onychomycosis Therapeutics Market Report" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The analysts forecast the Global Dermatophytic Onychomycosis Therapeutics market to grow at a CAGR of 7.28 percent over the period 2012-2016. One of the key factors contributing to this market...

2014-03-25 16:26:26

DUBLIN and LAVAL, Quebec, March 25, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Metronidazole 1.3% Vaginal Gel, an antibiotic for the treatment of bacterial vaginosis (BV). Actavis acquired the rights to Metronidazole 1.3% from Valeant Pharmaceuticals International in April 2013. Bacterial vaginosis...

2014-03-12 08:31:19

LYNDHURST, N.J., March 12, 2014 /PRNewswire/ -- Amerigen Pharmaceuticals Limited announces that its ANDA for carbidopa 25mg tablets has received final approval from the U.S. Food and Drug Administration. The product is a generic equivalent of Valeant's Lodosyn® and has been launched under an Amerigen Pharmaceuticals label. John Lowry, Amerigen's President & CEO commented: "We are very pleased to receive our first ANDA approval. This product was entirely self-developed and...

2014-03-06 12:27:00

The pharmaceutical company is committed to donating a portion of its Medicis® and Obagi® product sales every quarter for a combined donation goal of $1 million in one year. NEW YORK, March 6, 2014 /PRNewswire/ -- Valeant Pharmaceuticals North America, LLC, today announced it has donated $250,000 to the National Coalition Against Domestic Violence (NCADV). The donation is a reflection of Valeant's ongoing support and commitment to the wellbeing of women, and is the first of four checks the...

2014-02-27 12:27:41

LONDON, Feb. 27, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Global Parkinson's Disease Market 2012-2016 TechNavio's analysts forecast the Global Parkinson's Disease market to grow at a CAGR of 1.67 percent over the period 2012-2016. One of the key factors contributing to this market growth is the rise in the aging population. The Global Parkinson's Disease market has also been witnessing the transition toward using drugs that have new...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related